FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2485710866> ?p ?o ?g. }

• W2485710866 endingPage "560" @default.
• W2485710866 startingPage "549" @default.
• W2485710866 abstract "Glutamate excitotoxicity is a significant determinant of traumatic brain injury (TBI) pathophysiology. Elevated glutamate can damage neurons through activation of various glutamate receptors. Excessive extracellular glutamate also initiates astrocyte pathology through excessive uptake of Na+ through sodium-glutamate co-transporters. This chapter discusses a novel strategy for reducing glutamate toxicity following TBI by inhibiting the cleavage of N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate. NAAG is an abundant peptide found in the brain and is released from neurons after intense depolarization and functions as a selective agonist at metabotropic glutamate receptor subtype 3 (mGluR3), which is located on both neurons and astrocytes. NAAG is catabolized into NAA and glutamate by a specific carboxypeptidases. NAAG could play a significant role in modulating glutamate excitotoxicity if its rapid catabolism can be inhibited thereby conferring protection to the traumatized brain in several ways. First, NAAG reduces excessive glutamate release by activation of presynaptic mGluR3 autoreceptors. Second, by inhibiting the cleavage of NAAG into NAA and glutamate a secondary source of synaptic glutamate could be diminished. Third, activation of mGluR3 on astrocytes increases the expression of glutamate transporters thereby facilitating removal of excess glutamate from the synapse. Fourth, inhibiting the accumulation of the NAAG cleavage product, NAA, reduces NAA-Na+ co-transport and subsequent astrocyte Na+ overload. Overload of [Na+]i can initiate astrocyte pathology that subsequently impacts negatively on surrounding neurons. Thus, inhibition of carboxypeptidases represents a novel strategy for reducing glutamate excitotoxicity following TBI through multiple mechanisms. NAAG peptidase inhibition could provide new and important insights into glutamate excitotoxicity and lead to important insights into the dynamics of neuron-astrocyte interactions in TBI pathophysiology.An estimated 1.7 million persons per year sustain a TBI in the United States resulting in more than 230,000 hospitalizations and 50,000 deaths (Faul et al., 2010). Survivors of TBI are often left with long-term disability (approximately 85,000 new cases per year) encompassing a broad spectrum of physical, neurological, and psychological dysfunctions such as memory impairment and difficulties with attention and concentration (Thurman and Guerrero, 1999; Thurman et al., 1999). The annual economic cost to society for the care of head-injured patients has been estimated to exceed $25 billion (Goldstein, 1990). TBI research to date, including glutamate excitotoxicity pathways, has focused almost exclusively on the pathophysiology of injured neurons with very little attention paid to glial cells or the interaction between glia and neurons. Astrocytes, which play an important role in normal brain function, increasingly appear to play a critical role in perturbed brain functions associated with seizures and ischemia brain injury (Vernadakis 1996; Vesce et al., 1999). This chapter examines a novel method of reducing the damaging effects of elevated extracellular glutamate by manipulating a putative endogenous peptide neurotransmitter, N-acetylaspartylglutamate (NAAG). The role of NAAG in exogenous and endogenous brain cellular protection involves the interdependent nature of neuronal glial interactions and the critical involvement of glutamate excitotoxicity initiated by TBI.Previous therapeutic strategies targeting excitotoxicity in central nervous system (CNS) injury have focused on pharmacological blockade of various ionotropic and metabotropic glutamate receptors. Although laboratory results have often been impressive, translation into clinical applications have been overwhelmingly disappointing (Bullock et al., 1999; Narayan et al., 2002). However, a general perception from laboratory experiments is that excessive glutamate is indeed damaging to neurons (Bullock et al., 1999). This chapter discusses a novel strategy to reduce glutamate toxicity by simultaneously enhancing levels of an endogenous neurotransmitter peptide, NAAG, while reducing its cleavage products, N-acetylaspartate (NAA) and glutamate, through application of NAAG peptidase inhibitors. This approach is designed to reduce excitotoxicity through multiple mechanisms acting in concert.Three pathways of the NAAG neuropeptide story are depicted in Figure 38.1. The first pathway (highlighted in green) depicts how NAAG reduces glutamate release by activation of presynaptic metabotropic glutamate receptor subtype 3 (mGluR3) autoreceptors. This is based on data demonstrating that inhibition of NAAG cleavage elevates levels of extracellular NAAG and reduces extracellular levels of glutamate after TBI (Zhong et al., 2005). Because NAAG is hydrolyzed into NAA and glutamate, the first pathway also depicts how NAAG cleavage provides a secondary source of extracellular glutamate.A second pathway (highlighted in red in the figure) depicts elevated concentrations of NAAG peptide increasing glutamate uptake in astrocytes after TBI as a result of mGluR3 receptor activation on astrocytes. There is an established relationship between NAAG activation of mGluR3 on astrocytes and increased glutamate transport (Aronica et al., 2003; Yao et al., 2005). The expression and kinetics of glutamate transporters could be potentially increased by NAAG activating mGluR3 on astrocytes (Aronica et al., 2003). Thus, the extent of cellular protection afforded by NAAG peptidase inhibitors may not simply be because of reduced glutamate release, but also because of NAAG-induced enhancement of glutamate transport into astrocytes.A third pathway (highlighted in blue in the figure) depicts the role of NAA (a product of NAAG cleavage by NAAG peptidase) in astrocyte pathology after TBI. NAAG is exclusively stored and released in neurons, whereas NAAG peptidase is exclusively found on the surface of astrocytes (Neale et al., 2000). NAA is preferentially and overwhelmingly taken up by sodium-dependent transporters located on astrocytes (Sager et al., 1999b). The excessive NAA/Na+ cotransport into astrocytes after TBI initiates a pathological cascade in astrocytes related to elevated [Na+]i. Glutamate/Na+ cotransporters (GLT-1 and GLAST) located on astrocytes also initiates a Na+-dependent pathological cascade in astrocytes that eventually impacts upon survival of nearby neurons (Floyd et al., 2005).NAAG likely functions as an endogenous protective peptide through multiple pathways involving both neurons and astrocytes. However, NAAG is short-lived in the synapse because of its rapid catabolism by NAAG peptidases (glutamate carboxypeptidase II [GCP-II] and GCP-III), which diminishes the beneficial effects of NAAG. Application of NAAG peptidase inhibitors represents a novel method of enhancing the endogenous protective effects of NAAG by enhancing and sustaining concentrations of NAAG in the synapse." @default.
• W2485710866 created "2016-08-23" @default.
• W2485710866 creator A5087628481 @default.
• W2485710866 date "2015-01-01" @default.
• W2485710866 modified "2023-09-23" @default.
• W2485710866 title "Application of novel therapeutic agents for CNS injury: NAAG peptidase inhibitors" @default.
• W2485710866 cites W1483485226 @default.
• W2485710866 cites W1511613906 @default.
• W2485710866 cites W1543959669 @default.
• W2485710866 cites W1593228500 @default.
• W2485710866 cites W1600033495 @default.
• W2485710866 cites W1656784884 @default.
• W2485710866 cites W1745420251 @default.
• W2485710866 cites W1852807375 @default.
• W2485710866 cites W1869098121 @default.
• W2485710866 cites W1942797206 @default.
• W2485710866 cites W1953513934 @default.
• W2485710866 cites W1964238705 @default.
• W2485710866 cites W1966853859 @default.
• W2485710866 cites W1968639827 @default.
• W2485710866 cites W1968829729 @default.
• W2485710866 cites W1971053474 @default.
• W2485710866 cites W1973587217 @default.
• W2485710866 cites W1974879850 @default.
• W2485710866 cites W1975907304 @default.
• W2485710866 cites W1979054663 @default.
• W2485710866 cites W1980612042 @default.
• W2485710866 cites W1983076548 @default.
• W2485710866 cites W1983998585 @default.
• W2485710866 cites W1984132292 @default.
• W2485710866 cites W1985936353 @default.
• W2485710866 cites W1989264219 @default.
• W2485710866 cites W1992868992 @default.
• W2485710866 cites W1993298162 @default.
• W2485710866 cites W1993870032 @default.
• W2485710866 cites W1995028111 @default.
• W2485710866 cites W1995824684 @default.
• W2485710866 cites W1995830387 @default.
• W2485710866 cites W1998056500 @default.
• W2485710866 cites W1998196920 @default.
• W2485710866 cites W1998478437 @default.
• W2485710866 cites W2000040142 @default.
• W2485710866 cites W2005176833 @default.
• W2485710866 cites W2005620630 @default.
• W2485710866 cites W2008028204 @default.
• W2485710866 cites W2009229844 @default.
• W2485710866 cites W2013606557 @default.
• W2485710866 cites W2015218703 @default.
• W2485710866 cites W2015419726 @default.
• W2485710866 cites W2015565546 @default.
• W2485710866 cites W2016205446 @default.
• W2485710866 cites W2018436079 @default.
• W2485710866 cites W2018730959 @default.
• W2485710866 cites W2019815063 @default.
• W2485710866 cites W2024744319 @default.
• W2485710866 cites W2027416773 @default.
• W2485710866 cites W2027706964 @default.
• W2485710866 cites W2034679108 @default.
• W2485710866 cites W2034939822 @default.
• W2485710866 cites W2035135723 @default.
• W2485710866 cites W2035371282 @default.
• W2485710866 cites W2035586509 @default.
• W2485710866 cites W2036574824 @default.
• W2485710866 cites W2036712372 @default.
• W2485710866 cites W2038546082 @default.
• W2485710866 cites W2038583417 @default.
• W2485710866 cites W2039603325 @default.
• W2485710866 cites W2039894841 @default.
• W2485710866 cites W2041204070 @default.
• W2485710866 cites W2041962720 @default.
• W2485710866 cites W2044654696 @default.
• W2485710866 cites W2044745774 @default.
• W2485710866 cites W2044956956 @default.
• W2485710866 cites W2045498748 @default.
• W2485710866 cites W2045663952 @default.
• W2485710866 cites W2046108898 @default.
• W2485710866 cites W2049362778 @default.
• W2485710866 cites W2049659439 @default.
• W2485710866 cites W2050416880 @default.
• W2485710866 cites W2050419480 @default.
• W2485710866 cites W2050553360 @default.
• W2485710866 cites W2053114980 @default.
• W2485710866 cites W2055957245 @default.
• W2485710866 cites W2056768860 @default.
• W2485710866 cites W2061812167 @default.
• W2485710866 cites W2062513416 @default.
• W2485710866 cites W2066036370 @default.
• W2485710866 cites W2066439059 @default.
• W2485710866 cites W2067682780 @default.
• W2485710866 cites W2068220105 @default.
• W2485710866 cites W2072032770 @default.
• W2485710866 cites W2075457027 @default.
• W2485710866 cites W2075971331 @default.
• W2485710866 cites W2078389347 @default.
• W2485710866 cites W2081314299 @default.
• W2485710866 cites W2082879189 @default.
• W2485710866 cites W2084188408 @default.
• W2485710866 cites W2085360535 @default.

• next